| 摘要 |
The application is directed to haloalkyl-substituted compounds of Formula (I ), wherein R1, R1a, R2, R3, R4~ and E are as defined in the claims. The compoun ds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. Pharmaceutical compositions comprising these compounds and their use are also disclosed.
|
